Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.62 |
| ▸ | CA1 | P00915 | 6/20 | 0.62 |
| ▸ | CA9 | Q16790 | 5/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 4/20 | 0.57 |
| ▸ | MMP9 | P14780 | 4/20 | 0.57 |
| ▸ | MMP1 | P03956 | 3/20 | 0.57 |
| ▸ | MMP13 | P45452 | 3/20 | 0.57 |
| ▸ | MMP3 | P08254 | 2/20 | 0.57 |
| ▸ | MMP7 | P09237 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 2/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25650178 | 0.92 | GAA (0.65) | CA2CA1CA9CA7GAA | |
| SCHEMBL30613610 | 0.85 | MMP2 (0.57) | CA2CA1CA9CA7GAA | |
| SCHEMBL7874523 | 0.85 | GBA1 (0.57) | CA2CA1CA9CA7GAA | |
| SCHEMBL6500063 | 0.83 | CA2 (0.62) | CA2CA1CA9CA7GAA | |
| SCHEMBL2338607 | 0.82 | CA2 (0.62) | CA2CA1CA9CA7ALDH1A1 | |
| SCHEMBL2338611 | 0.82 | CA2 (0.62) | CA2CA1CA9CA7ALDH1A1 | |
| SCHEMBL19165633 | 0.80 | GAA (0.52) | CA2CA1CA9CA7GAA | |
| SCHEMBL19165392 | 0.80 | GAA (0.52) | CA2CA1CA9CA7GAA | |
| SCHEMBL6130629 | 0.80 | MMP2 (0.61) | CA2CA1CA9CA7GAA | |
| Benzene SCHEMBL29019330 | 0.80 | ALDH1A1 (0.59) | CA2CA1CA9CA7GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | CA2 374/4885CA1 2112/4885CA9 619/4885 |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | CA2 443/4885CA1 2470/4885CA9 708/4885 |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | CA2 497/4885CA1 401/4885CA9 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.